Friday, October 23, 2020 10:36:30 AM
GeeGee, I respect your opinion and I'm going to research it more. Will report back.
I don't know how it hits the lungs differently like you mentioned so that's an area I will focus on.
The second part you are assuming we don't need need a high number of cases because of lower P-Value but we simply won't know that until the data is unblinded. We don't know at this point if it has superior efficacy or not.
We only know of 21 patients from a Dr that used to work with Sami Said. And until it's peer reviewed call me skeptical.
I don't know how it hits the lungs differently like you mentioned so that's an area I will focus on.
The second part you are assuming we don't need need a high number of cases because of lower P-Value but we simply won't know that until the data is unblinded. We don't know at this point if it has superior efficacy or not.
We only know of 21 patients from a Dr that used to work with Sami Said. And until it's peer reviewed call me skeptical.
PROUD MEMBER OF THE WHALES HAIRY BACK CLUB
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
